Cullinan Therapeutics, Inc. (NASDAQ: CGEM)
$12.0600
-0.1400 ( -2.51% ) 76.6K
Cullinan Therapeutics Inc is a biopharmaceutical company. It has diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, create differentiated ideas, identify the appropriate targets, and select the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications.
Market Data
Open
$12.0600
Previous close
$12.2000
Volume
76.6K
Market cap
$698.73M
Day range
$11.1100 - $13.1100
52 week range
$10.0000 - $30.1886
SEC Filings
Form Type | Description | Pages | Date |
---|---|---|---|
4 | Insider transactions | 1 | Dec 27, 2024 |
4 | Insider transactions | 1 | Dec 20, 2024 |
4 | Insider transactions | 1 | Dec 20, 2024 |
4 | Insider transactions | 1 | Dec 20, 2024 |
4 | Insider transactions | 1 | Dec 16, 2024 |
8-k | 8K-related | 12 | Nov 07, 2024 |
10-q | Quarterly Reports | 57 | Nov 07, 2024 |
4 | Insider transactions | 1 | Nov 07, 2024 |
8-k | 8K-related | 68 | Oct 16, 2024 |
8-k | 8K-related | 12 | Sep 17, 2024 |